Quantitative sensory testing of pain in osteoporosis: a pilot randomized clinical trial with magnesium supplementation.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Magnesium is involved in pain mechanisms, mood disorders and also in bone homeostasis.

Protocol, statistical analysis plan, participant data and other materials (including data dictionary) can be accessed on request to the corresponding author.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, women only.

Endpoints were quantified before and 1 year after treatment as spontaneous pain, anxiety, depression and sleep quality, as well as quantitative sensory testing of pain sensitivity by thermal thresholds and conditioned pain modulation (CPM), a psychophysical marker of the functionality of pain modulation at spinal level.

How the Study Was Run

In design terms this was a randomized and pilot study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

The subject headings attached to it are Pilot Projects, Osteoporosis, Postmenopausal, Magnesium, Zoledronic Acid, Pain, Pain Measurement and Dietary Supplements.

The authors tagged it with the keywords Bone, Magnesium supplementation and Quantitative sensory testing.

What This Means in Plain Language

The paper is a randomized and pilot study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Aging clinical and experimental research), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.